

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. **(Previously presented)** An oligopeptide having the amino acid sequence:
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
2. **(Previously presented)** The oligopeptide according to Claim 1 wherein one or more of the amino acids of said oligopeptide are D isomers.
3. **(Previously presented)** The oligopeptide according to Claim 2, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers.
4. **(Currently amended)** The oligopeptide according to ~~any one of Claims 1 to 3~~ Claim 1, wherein the terminal carboxyl group of said oligopeptide is amidated.
5. **(Currently amended)** The oligopeptide according to ~~any one of Claims 1 to 4~~ Claim 1, wherein said oligopeptide is in salt form.
6. **(Currently amended)** The oligopeptide according to ~~Claim 5~~ Claim 1, wherein said the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
7. **(Original)** An oligopeptide having the structural formula:
H-(D)Arg-(D)nL-(D)nL-(D)nL-(D)Arg-(D)nL-(D)nL-(D)nL-Gly-(D)Tyr-NH₂.
8. **(Original)** A pharmaceutical composition comprising an oligopeptide according to any one of Claims 1 to 7 and a pharmaceutically acceptable medium.
9. **(Original)** The pharmaceutical composition according to Claim 8, wherein said pharmaceutically acceptable medium comprises an excipient.

Serial No.: 10/780,321
Filing Date: February 17, 2004

10. (Original) The pharmaceutical composition according to Claim 9, wherein said excipient comprises mannitol.

11. (New) The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is amidated.

12. (New) The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is amidated.

13. (New) The oligopeptide according to Claim 2, wherein said oligopeptide is in salt form.

14. (New) The oligopeptide according to Claim 3, wherein said oligopeptide is in salt form.

15. (New) The oligopeptide according to Claim 4, wherein said oligopeptide is in salt form.

16. (New) The oligopeptide according to Claim 5, wherein said oligopeptide is in salt form.

17. (New) The oligopeptide according to Claim 6, wherein said oligopeptide is in salt form.

18. (New) The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

19. (New) The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

20. (New) The oligopeptide according to Claim 4, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

21. (New) The oligopeptide according to Claim 5, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

22. (New) The oligopeptide according to Claim 6, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

23. (New) The oligopeptide according to Claim 7, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
24. (New) The oligopeptide according to Claim 8, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
25. (New) The oligopeptide according to Claim 9, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
26. (New) The oligopeptide according to Claim 10, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
27. (New) The oligopeptide according to Claim 11, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
28. (New) The oligopeptide according to Claim 12, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
29. (New) A pharmaceutical composition comprising an oligopeptide according to any one of Claims 11 to 28 and a pharmaceutically acceptable medium.
30. (New) The pharmaceutical composition according to Claim 29, wherein said pharmaceutically acceptable medium comprises an excipient.
31. (New) The pharmaceutical composition according to Claim 30, wherein said excipient comprises mannitol.